[1] 武 婷,武 莉,李 乐,等. CYP3A4*1G和CYP3A5*3基因多态性对颌面外科手术患者舒芬太尼代谢的影响[J].中国美容医学,2021,(7):83-86.
　 WU Ting,WU Li,LI Le,et al. The Effect of Genetic Polymorphism Interaction between CYP3A4*1G and CYP3A5*3for Maxillofacial Surgery with Metabolism of Sufentanil[J].Medical Aesthetics and Beauty,2021,(7):83-86.
点击复制

 CYP3A4*1G和CYP3A5*3基因多态性对颌面外科手术患者舒芬太尼代谢的
影响
()
分享到：

《中国美容医学》[ISSN:1008-6445/CN:61-1347/R]

卷:
期数:
2021年7期
页码:
83-86
栏目:
出版日期:
2021-07-10

文章信息/Info

Title:
 The Effect of Genetic Polymorphism Interaction between CYP3A4*1G and CYP3A5*3
for Maxillofacial Surgery with Metabolism of Sufentanil
文章编号:
1008-6455(2021)07-0083-04
作者:
 武 婷1; 2; 武 莉3; 李 乐1; 2; 张丽娜1; 2 ; 潘 旭1; 2 ; 王 智1; 2
Author(s):
 WU Ting1; 2; WU Li3; LI Le1; 2; ZHANG Li-na1; 2; PAN Xu1; 2; WANG Zhi1; 2
关键词:
 [关键词]CYP3A4酶; CYP3A5酶; 基因多态性; 舒芬太尼; 药物代谢
分类号:
R73
文献标志码:
A
摘要:
[摘要]目的：研究CYP3A4*1G和CYP3A5*3基因多态性相互作用对颌面外科手术患者舒芬太尼药物代谢的影响。方法：选取2018
年10月-2019年12月在西安交通大学口腔医院颌面外科择期全麻下行颌面外科手术的88例患者为研究对象，年龄21～69岁，
根据美国麻醉医师学会(ASA)分级为ASAⅠ或Ⅱ级。采用聚合酶链(PCR)-基因测序法对CYP3A4*1G和CYP3A5*3基因位点进行检
测，根据两个基因的不同基因分型相互结合，分为Ⅰ、Ⅱ、Ⅲ+Ⅳ 三组。待患者进行麻醉诱导后，0.5h时抽取患者的外周静
脉血液，采用高效液相色谱法(HPLC)检测患者体内舒芬太尼的血药浓度。术后24h时,对患者进行视觉模拟评分(VAS)评价疼
痛程度，并记录患者24h内舒芬太尼的用量。结果：Ⅰ、Ⅱ、Ⅲ+Ⅳ 三组患者术中舒芬太尼血药浓度及术后24h VAS评分比较
有统计学差异(P＜0.05)。结论：CYP3A4*1G与CYP3A5*3共同影响舒芬太尼的体内代谢，两者基因多态性相结合，可作为术中
指导舒芬太尼个体化用药的指标。

Abstract:

(1.Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, Xi,an 710004,Shaanxi,China;
2.Department of Anesthesiology, Hospital of stomatology,Xi,an Jiaotong University,Xi,an 710004,Shaanxi,China;3.Department
of Anesthesiology, Shanxi Provincial People’s Hospital, Taiyuan 030012,Shanxi,China )
Abstract: Objective This study aims to study the effect of genetic polymorphism interaction between CYP3A4*1G and
CYP3A5*3 for Maxillofacial surgery with metabolism of sufentanil. Methods A total of 88 patients who underwent
Maxillofacial surgery under elective general anesthesia at the Department of maxillofacial surgery, Stomatological Hospital of
Xi’an Jiaotong University from October 2018 to December 2019 were selected, aged 21-69, rated ASA Ⅰ or Ⅱ according to
the American college of anesthesiologists (ASA). To detect the locus of CYP3A4*1G and CYP3A5*3 with Polymerase chain
(PCR) - gene sequencing, then divide them into three parts according dfferent genetic typing’s combining, respectively are
Ⅰ,Ⅱand Ⅲ+Ⅳ. Draw patients’ peripheral venous blood half a hour after they were anesthesia induction, and detect the blood
concentration of sufentanil with high performance liquid chromatography(HPLC). Visual analogue scale (VAS) was used to
evaluate the degree of pain at 24h after surgery, and the dosage of sufentanil was recorded within 24h. Results Ⅰ,Ⅱand Ⅲ+Ⅳ
three parts patients’total dosage of sufentanil and VAS scores exists statistic difference (P ＜0.05). Conclusion CYP3A4*1G
and CYP3A5*3 can have a genetic polymorphism interaction and affect metabolism of sufentanil together, therefore, it can be
used as an intraoperative indicator to guide sufentanil individual medication.
Key words: CYP3A4;CYP3A5;gene polymorphism; sufentanil;drug metabolism
更新日期/Last Update: 2021-08-03